Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
imatinib (Glivec®)
Reference No. 1653
Publication date:
25/07/2014
Last review date:
08/05/2017
Appraisal information
imatinib (Glivec®) 100 mg film-coated tablet
imatinib (Glivec®) 400 mg film-coated tablet
Company:
Novartis Pharmaceuticals UK Ltd
BNF category:
Malignant disease and immunosupression
NMG meeting date:
14/05/2014
AWMSG meeting date:
11/06/2014
Submission Type:
Full Submission
Status:
Superseded
Advice No:
1414
Ratification by Welsh Government:
24/07/2014
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA326) NICE GUIDANCE ISSUED NOVEMBER 2014 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). Imatinib (Glivec®) is recommended for restricted use within NHS Wales. Imatinib (Glivec®) should be restricted for use in the following subpopulation within its licensed indication for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of KIT (CD117)-positive gastrointestinal stromal tumours. Patients who have low or very low risk of recurrence should not receive adjuvant treatment. Imatinib (Glivec®) should be restricted for use in patients who are considered to be at high risk of relapse according to the Miettinen criteria. Imatinib (Glivec®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
imatinib (Glivec) 1653 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
imatinib (Glivec) 1653 ASAR
Clinical Expert (CE) Summary
Download
imatinib (Glivec) 1653 CE summary